Global Cholera Vaccines Market Growth, Trends, and Forecasts 2019-2024 -

DUBLIN--()--The "Cholera Vaccines Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to's offering.

The growth of the global cholera vaccines market can be attributed to multiple factors, such as the increasing incidences of cholera, rising initiatives by public and private entities, and growing awareness regarding cholera across the world.

In 2017, 10 million doses of oral cholera vaccines were funded in affected countries via stockpile. This stockpile has been accessed 52 times since the funding, by 18 countries across the world, including Sierra Leone and Haiti.

However, a lack of access to adequate care for cholera, coupled with a large number of unreported cases, are expected to pull back the growth of the market.

Key Market Trends

Whole-cell V. cholerae O1 with a Recombinant B-subunit Segment Captures the Largest Market Share

This oral cholera vaccine containing a combination of recombinant B-subunit and killed the whole cell V. cholerae O1 has been marketed since early 1990. This vaccine is observed to provide 80-90% protection for six months, post immunization, and in all the cases of immunization of vaccines aged more than 2 years.

In addition to this, this vaccines shows around 50% of protection even after three years of immunization. Hence, the efficacy and long-lasting post immunization protections of the vaccine are expected to propel the segment's growth over the forecast period.

North America is Expected to Grow at a High Rate over the Forecast Period

Asia-Pacific captures the largest market share in the global cholera vaccines market, followed by Europe. This can be attributed to the high incidence rate, growing awareness, and availability of efficient preventive solutions. The APAC market experienced exceptional growth since the launch of the oral cholera vaccine, Shanchol, in 2009.

According to the statistics of WHO, 42 countries reported 172,454 cases of cholera in 2015, with 1,304 deaths. These statistics showed an overall decrease of 9% from the previous year, owing to growing immunization in the region. On the other hand, North America is expected to exhibit the fastest growth rate over the forecast period, owing to the launch of the first ever oral cholera vaccine, Vaxchora, in 2016, and the rise in the number of immigrants.

Competitive Landscape

Some of the significant companies in the market are AstraZeneca, Shantha Biotechnics Private Limited, Valneva, Merck & Co, and PaxVax. The major market players, in order to retain a strong market position, focus on mergers, acquisitions, and product innovation.

Also, licensing rights on the vaccines of some major companies give them the leverage of a strong market foothold. For instance, the licensing rights of Dukoral were conferred to Valneva, post-acquisition of Crucell Sweden, in turn, strengthening the company's cholera vaccine portfolio and overall market position.

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Incidences of Cholera

4.2.2 Rising Initiatives and Awareness Regarding Immunization

4.3 Market Restraints

4.3.1 Lack of Access to Adequate Treatment

4.4 Porter's Five Forces Analysis


5.1 Vaccine Type

5.1.1 Whole cell V. cholerae O1 with Recombinant B-subunit

5.1.2 Killed Oral O1 and O139

5.2 Product

5.2.1 Vaxchora

5.2.2 Dukoral

5.2.3 Shanchol

5.2.4 Other Products

5.3 Geography

5.3.1 North America US Canada Mexico

5.3.2 Europe Germany UK France Italy Spain Rest of Europe

5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific

5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa

5.3.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles

6.1.1 Astellas Pharma Inc.

6.1.2 AstraZeneca

6.1.3 Emergent BioSolutions Inc.

6.1.4 GlaxoSmithKline PLC (GSK)

6.1.5 Merck & Co. Inc.

6.1.6 Mitsubishi Tanabe Pharma Corporation

6.1.7 PaxVax Inc.

6.1.8 Pfizer Inc.

6.1.9 Shantha Biotechnics Private Limited

6.1.10 Takeda Pharmaceutical Co. Ltd.

6.1.11 Valneva SE


For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines